PMID- 12662149
OWN - NLM
STAT- MEDLINE
DCOM- 20040713
LR  - 20151119
IS  - 1471-2598 (Print)
IS  - 1471-2598 (Linking)
VI  - 3
IP  - 2
DP  - 2003 Apr
TI  - Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal 
      antibody.
PG  - 371-6
AB  - The immunoglobulin E (IgE) antibody plays a central role in the allergic immune 
      responses, such as those which characterise allergic bronchial asthma. The 
      ability to reduce circulating IgE by using anti-IgE antibodies represents a novel 
      therapeutic approach for IgE-mediated allergic diseases. Omalizumab 
      (rhuMAb-E25/Xolair Genentech, USA/Tanox, Inc., USA/Novartis Pharma AG, 
      Switzerland) is a non-anaphylactogen humanised murine monoclonal antibody which 
      binds to circulating IgE. Therapeutic use of an anti-IgE antibody in the 
      treatment of asthma was first suggested in preliminary studies in which 
      omalizumab demonstrated efficacy in attenuating both the early- and late-phase 
      bronchial responses to inhaled allergens in atopic subjects. Treatment with 
      omalizumab has demonstrated both a significant beneficial effect on a number of 
      measures, and a favourable safety profile. It reduces the frequency of asthma 
      exacerbations and the need for inhaled corticosteroids (ICSs), and improves 
      asthma symptoms, lung function and quality of life. The anti-IgE approach to 
      asthma treatment has a number of further potential advantages, such as the 
      treatment of other concomitant atopic diseases (allergic conjunctivitis and 
      rhinitis, atopic dermatitis and food allergy), regardless of the type of allergic 
      sensitisation (seasonal or perennial). On the basis of several studies, 
      omalizumab is likely to provide a new strategy for treating atopic asthma.
FAU - D'Amato, Gennaro
AU  - D'Amato G
AD  - Division of Pneumology and Allergology, High Speciality Hospital'A Cardelli, 
      Naples, Italy. gdamato@qubisoft.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*etiology/*therapy
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Hypersensitivity/*complications/*therapy
MH  - Immunoglobulin E/*immunology/physiology
MH  - Omalizumab
RF  - 29
EDAT- 2003/03/29 05:00
MHDA- 2004/07/14 05:00
CRDT- 2003/03/29 05:00
PHST- 2003/03/29 05:00 [pubmed]
PHST- 2004/07/14 05:00 [medline]
PHST- 2003/03/29 05:00 [entrez]
PST - ppublish
SO  - Expert Opin Biol Ther. 2003 Apr;3(2):371-6.